Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)

NCT03838042 is registered in ClinicalTrials.gov with University Hospital Heidelberg as lead sponsor.

NCT NCT03838042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03838042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies (INFORM2-NivEnt)
Lead sponsor
University Hospital Heidelberg
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 26, 2020
Completion date
June 30, 2027
Enrollment
91 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cns tumor, solid tumor